Medindia

X

Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System

Wednesday, December 19, 2007 General News J E 4
Advertisement
WAYNE, Pa., Dec. 18 Escalon Medical Corp.(Nasdaq Capital Market: ESMC) today announced that its Drew Scientificsubsidiary received 510(k) clearance from the U.S. Food and DrugAdministration (FDA) to market the D3 Hematology System, an automaticthree-part differential Hematology Analyzer. Drew Scientific plans tocommence shipments of the product in the United States by month-end.

"The FDA clearance represents a major step for Drew, as it now providestwo upgraded instruments for sale in fiscal 2008 along with the TRILOGYAnalyzer that was approved in July," said Frank Matuszak, Drew's VicePresident of Sales and Marketing. "For the past twelve months, we havesuccessfully distributed the D3 System outside of the United States. Weexpect that the D3 will be equally well received in the U.S. marketplace."

The D3 Hematology System adds to the Company's wide range of top qualityand leading edge hematology systems. This flexible and easy-to-use instrumentoffers simple installation, low maintenance and immediate user acceptance andproductivity. The D3 incorporates advanced technology for superiorreliability of 3-part differential blood analysis. Features include:

For additional information on the D3 Hematology System, please visit theDrew Scientific web site at www.drew-scientific.com.

Doug Nickols, President of Drew Scientific, commented, "FDA clearance isanother important step in the continued development of the D3 HematologySystem. With this advancement and continued growing interest in the D3 Systemabroad, we expect to accelerate the pace of our analyzer placementsworldwide."

Drew Scientific is a diagnostics company specializing in the design,manufacture and distribution of instruments for blood cell counting and bloodanalysis. Drew Scientific is focused on providing instrumentation andconsumables for the physician office and veterinary office laboratories. DrewScientific also supplies the reagent and other consumable materials needed tooperate the instruments.

Founded in 1987, Escalon develops markets and distributes ophthalmicdiagnostic, surgical and pharmaceutical products as well as vascular accessdevices. Drew Scientific, which operates as a separate business unit,provides instrumentation and consumables for the diagnosis and monitoring ofmedical disorders in the areas of diabetes, cardiovascular diseases andhematology, as well as veterinary hematology and blood chemistry. Escalonseeks to utilize strategic partnerships to help finance its developmentprograms and is also seeking acquisitions to further diversify its productline to achieve critical mass in sales and take better advantage of Escalon'sdistribution capabilities, although any such partnerships or acquisitions maynot occur. Escalon has headquarters in Wayne, Pennsylvania and manufacturingoperations in Long Island, New York, New Berlin, Wisconsin, Dallas, Texas,Waterbury, Connecticut and Barrow-in-Furness, U.K.

Note: This press release contains statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, includingstatements about the Company's future prospects. They are based on theCompany's current expectations and are subject to a number of uncertaintiesand risks, and actual results may differ materially. The uncertainties andrisks include whether the Company is able to

Further information about these and other relevant risks and uncertaintiesmay be found in the Company's report on Form 10-K, and its other filings withthe Securities and Exchange Commission, all of which are available from theCommission as well as other sources.-- Low reagent consumption and very small sample size to minimize laboratory waste. -- Advanced user flexibility with easy-to-use built-in color touch screen, providing on screen histograms and storage of up to 500 records and QC statistic
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Clinical Trial Participation Unaffected by Disclos...
S
Longs Drug Stores Corporation Commits $225,000 to ...